-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACM-001 in Cancer Anorexia-Cachexia Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACM-001 in Cancer Anorexia-Cachexia Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ACM-001 in Cancer Anorexia-Cachexia SyndromeDrug Details:Espindolol (ACM-001) is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ACM-001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ACM-001 Drug Details Espindolol (ACM-001) is under development for the treatment of cachexia related...
-
Product Insights
Mucositis Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Mucositis Global Clinical Trials Review, H1, 2018" provides an overview of Mucositis clinical trials scenario. This report provides top line data relating to the clinical trials on Mucositis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...